A patient sitting in a hospital for hours while receiving treatment is a familiar scene in modern healthcare. For many people living with chronic conditions, these visits become a routine part of life. Treatments can be time-consuming, travel can be exhausting, and scheduling appointments often adds another layer of stress. For years, this was simply accepted as part of receiving care.
But a group of innovators believed there could be a better way.
That belief led to the creation of Enable Injections, a medical technology company focused on making complex drug treatments easier and more convenient for patients. Through its wearable drug delivery platform, the company is helping transform how certain medications are administered, allowing patients greater flexibility and independence while receiving treatment.
Today, Enable Injections is recognized as one of the companies helping shape the future of smart drug delivery systems. Its technology combines engineering innovation with a strong focus on patient experience, creating solutions designed to simplify treatment without compromising effectiveness.
Understanding Smart Drug Delivery Systems
Healthcare continues to evolve as technology improves the way medicines are developed, distributed, and administered. One of the most important developments in recent years has been the growth of smart drug delivery systems.
A smart drug delivery system is designed to improve how medication reaches patients. These systems focus on making treatment more efficient, convenient, and patient-friendly. Instead of relying solely on traditional methods such as intravenous infusions in healthcare facilities, smart drug delivery technologies help patients receive treatment in ways that better fit their daily lives.
The growing use of biologic medicines has increased demand for advanced delivery methods. Many biologic therapies require larger volumes of medication than traditional injections can comfortably provide. As a result, healthcare companies have been searching for solutions that make administration easier while maintaining safety and effectiveness.
Enable Injections entered this space with a clear mission: create a technology that allows patients to receive large-volume therapies more conveniently and comfortably.
The Story Behind Enable Injections
Enable Injections was founded to address a challenge faced by both patients and healthcare providers. As more advanced therapies entered the market, traditional methods of administration often remained complicated and inconvenient.
The company focused on developing technology that could move certain treatments beyond hospitals and infusion centers. Rather than requiring patients to spend significant time receiving therapy in clinical settings, Enable Injections envisioned a solution that would allow treatment in more comfortable environments.
This vision led to the development of the enFuse® On-Body Delivery System, the company’s flagship technology platform. The goal was simple but ambitious. Enable Injections wanted to create a delivery system capable of administering larger volumes of medication through a wearable device while maintaining ease of use for patients. Years of engineering, testing, and collaboration eventually transformed that vision into reality.
The enFuse On-Body Delivery System
At the center of Enable Injections’ success is the enFuse On-Body Delivery System.
The wearable device is designed to deliver larger volumes of medication subcutaneously, meaning under the skin rather than directly into a vein. This approach offers an alternative to certain traditional infusion methods. Patients apply the device to the body and activate it according to instructions provided by healthcare professionals. The system is designed to handle the medication delivery process while remaining discreet and comfortable for users.
One of the most notable features of enFuse is its purely mechanical design. Unlike many modern wearable devices that rely on electronics or batteries, enFuse operates mechanically. This design helps simplify the user experience while reducing device complexity. The system is also designed with a hidden needle mechanism, helping improve comfort and confidence for patients who may feel anxious about injections.
By focusing on simplicity and usability, Enable Injections created a platform that supports both healthcare providers and patients while addressing challenges associated with large-volume drug administration.
Achieving Important Regulatory Milestones
Developing innovative healthcare technology is only one part of the journey. Regulatory approval plays an equally important role in bringing new solutions to patients. Enable Injections reached a major milestone in 2023 when the U.S. Food and Drug Administration approved the EMPAVELI Injector for use with EMPAVELI in adults with paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
The approval represented the first commercial application of the company’s enFuse technology platform in the United States. It demonstrated confidence in the technology and marked an important step forward for wearable drug delivery systems. The company continued building momentum beyond the United States.
In 2025, the enFuse platform received European Union Medical Device Regulation CE Mark approval, allowing broader access across European markets. The technology also achieved registration with the United Kingdom’s Medicines and Healthcare products Regulatory Agency. Additional regulatory approvals followed in Brazil through ANVISA and in Saudi Arabia through the Saudi Food and Drug Authority. These milestones highlight the growing international acceptance of Enable Injections’ technology and support the company’s efforts to expand patient access globally.
Industry Recognition for Innovation
Innovation in healthcare often attracts attention from industry organizations, and Enable Injections has received recognition for its work. In 2023, the company was named to Fierce Medtech’s Fierce 15 list, which highlights innovative private medical technology companies making significant contributions to the healthcare industry. The recognition came during a period of important growth for the company, following the commercial progress of its enFuse technology platform.
Enable Injections also received the REDI Cincinnati James A. Wuenker Growth Award in 2023, reflecting its business expansion and contribution to economic development in the region. These recognitions underscore the company’s reputation as an innovator in the drug delivery sector and demonstrate the industry’s interest in technologies that improve patient care.
Funding That Supports Growth and Expansion
Developing advanced medical technologies requires substantial investment. Enable Injections has attracted significant support from investors who believe in the company’s vision and technology. One of the company’s most notable financing achievements came in January 2022 when it announced a $215 million Series C funding round. The financing was led by Magnetar Capital and included participation from several investors, including Sanofi.
The funding provided resources to expand manufacturing operations, support commercialization efforts, and advance future development programs. The relationship between Enable Injections and Sanofi extends beyond investment. The global pharmaceutical company has worked with Enable Injections through strategic collaborations focused on drug delivery innovation.
In January 2026, Sanofi announced an additional $30 million investment in Enable Injections. According to the company, the funding supports manufacturing expansion, supply chain development, and commercial growth initiatives. These investments reflect confidence in both the technology and the company’s long-term potential within the healthcare industry.
Strategic Partnerships Drive Global Reach
Partnerships have played a critical role in Enable Injections’ growth strategy. The company collaborates with major pharmaceutical organizations that seek innovative ways to deliver therapies to patients. These relationships allow pharmaceutical companies to combine their medicines with Enable Injections’ delivery technology.
One of the company’s important collaborations involves Roche. The partnership provides opportunities to apply enFuse technology to selected Roche development programs. The agreement demonstrates growing interest among pharmaceutical companies in delivery solutions that improve patient convenience.
Enable Injections has also entered into agreements with Swedish Orphan Biovitrum AB, commonly known as Sobi. Through these collaborations, the company supports the development and distribution of therapies that incorporate its wearable delivery platform. These partnerships strengthen Enable Injections’ global presence while helping bring advanced treatment options to patients in multiple markets.
Mike Hooven’s Education and Leadership Journey
Behind every successful healthcare company is leadership capable of turning ideas into real-world solutions. At Enable Injections, that leadership comes from Michael D. Hooven. Mike Hooven serves as Chairman and Chief Executive Officer of the company. He brings decades of experience in medical technology innovation and entrepreneurship.
His educational journey began at the University of Michigan College of Engineering, where he earned a Bachelor of Science degree in Physics. He later completed a Master of Science degree in Mechanical Engineering at the same institution. This combination of scientific and engineering education provided a strong foundation for a career focused on solving complex healthcare challenges. Before founding Enable Injections, Hooven built an impressive track record in the medical device industry. Throughout his career, he has founded multiple medical technology companies and contributed to numerous innovations that have influenced patient care.
He is particularly well known for his involvement with AtriCure, a company focused on surgical solutions for cardiac conditions. His work in the medical device sector has earned recognition for both innovation and entrepreneurship. At Enable Injections, Hooven played a central role in guiding the development of the enFuse platform. He helped shape the company’s mission of improving patient experiences while creating technology that addresses practical healthcare challenges.
Under his leadership, the company has progressed from an ambitious concept to an organization with international regulatory approvals, major pharmaceutical partnerships, and commercial success. His focus on patient-centered innovation continues to influence the direction of the company and its long-term strategy.
Improving the Patient Experience
While technology often receives the spotlight, the ultimate purpose of healthcare innovation is improving people’s lives. Enable Injections built its platform around the idea that patients deserve treatment experiences that fit more naturally into everyday life. The company understands that convenience can have a meaningful impact on quality of life, particularly for individuals managing chronic conditions.
The wearable design of enFuse aims to reduce treatment burdens by supporting administration outside traditional healthcare settings when appropriate. This flexibility can help patients spend less time arranging appointments and more time focusing on their personal and professional lives. As healthcare systems continue searching for ways to improve efficiency while maintaining high-quality care, technologies that empower patients are becoming increasingly important. Enable Injections’ approach aligns with this broader movement toward patient-centered healthcare.
Looking Toward the Future
The healthcare industry continues to evolve, and the demand for innovative drug delivery solutions is expected to grow alongside advances in medicine. Biologic therapies are becoming increasingly important in treating complex diseases, creating new opportunities for technologies capable of simplifying administration. Enable Injections is positioned to play an important role in this transformation.
The company continues expanding its partnerships, manufacturing capabilities, and international presence while supporting the development of new therapies that use the enFuse platform. Its journey reflects a broader trend within healthcare: the shift toward solutions that improve both treatment effectiveness and patient experience.
From its beginnings as a technology-driven startup to its current position as a recognized innovator in drug delivery, Enable Injections has demonstrated how thoughtful engineering can address real healthcare challenges. By focusing on patient needs, advancing wearable drug delivery technology, and building strong industry partnerships, the company continues helping shape the future of smart drug delivery systems. As healthcare moves toward more personalized and convenient treatment models, Enable Injections stands as an example of how innovation can make a meaningful difference in the lives of patients around the world.
